Systemic Mastocytosis clinical trials at UCSF

• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

  Sorry, in progress, not accepting new patients

  This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

  San Francisco, California and other locations

Last updated: April 16, 2021